Disc Medicine, Inc. (NASDAQ:IRON) Holdings Cut by Wellington Management Group LLP

Wellington Management Group LLP decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,395,405 shares of the company's stock after selling 444,821 shares during the quarter. Wellington Management Group LLP owned approximately 4.69% of Disc Medicine worth $88,469,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in Disc Medicine during the third quarter worth about $146,000. Intech Investment Management LLC acquired a new stake in Disc Medicine during the third quarter worth about $228,000. KLP Kapitalforvaltning AS acquired a new stake in Disc Medicine during the fourth quarter worth about $235,000. Teacher Retirement System of Texas raised its stake in Disc Medicine by 8.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after acquiring an additional 396 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $309,000. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Stock Down 10.1 %

NASDAQ:IRON traded down $3.90 during trading hours on Thursday, reaching $34.80. 78,204 shares of the company's stock were exchanged, compared to its average volume of 344,622. The company has a market capitalization of $1.20 billion, a P/E ratio of -8.76 and a beta of 0.77. Disc Medicine, Inc. has a 12 month low of $25.64 and a 12 month high of $68.73. The business's 50-day simple moving average is $51.59 and its two-hundred day simple moving average is $55.67.

Remove Ads

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on IRON. TD Cowen began coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating on the stock. Stifel Nicolaus raised their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Cantor Fitzgerald raised their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Wedbush restated an "outperform" rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Disc Medicine has a consensus rating of "Buy" and a consensus target price of $93.80.

Insider Buying and Selling

In related news, insider Rahul Khara sold 7,500 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $55.54, for a total transaction of $416,550.00. Following the completion of the sale, the insider now directly owns 14,035 shares in the company, valued at approximately $779,503.90. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Pamela Stephenson sold 3,137 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,217.46. Following the completion of the sale, the insider now owns 69,529 shares of the company's stock, valued at approximately $3,794,892.82. This trade represents a 4.32 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 361,690 shares of company stock worth $19,648,094. Corporate insiders own 4.24% of the company's stock.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.